FindMyKOL
Clinical trialNCT05768139RecruitingPhase 1/2Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139 is a phase 1/2 interventional trial sponsored by Eli Lilly and Company. As of 21 Nov 2026, it is recruiting participants. It studies Abemaciclib, Anastrozole, Exemestane, Fulvestrant and 7 more drugs in Breast Cancer and Solid Tumors, Adult. The registry lists an enrollment of 880 participants at 65 sites in 9 countries. The registry lists a start date of 17 Apr 2023 and a primary completion date of 31 Jul 2030. 4 of its registered investigators have a FindMyKOL profile.

SponsorEli Lilly and Company →Enrollment880Breast CancerSolid Tumors, Adult
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05768139
FieldValue
Registry IDNCT05768139
StatusRecruiting
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorEli Lilly and Company
Enrollment880
Registered sites65
Countries9
ConditionsBreast Cancer and Solid Tumors, Adult
DrugsAbemaciclib, Anastrozole, Exemestane, Fulvestrant, Imlunestrant, Letrozole, Metformin, Palbociclib, Ribociclib, Tersolisib and Tamoxifen
Start17 Apr 2023
Primary completion31 Jul 2030
Study completion31 Jul 2030
Last update posted7 Jul 2026
Other registry IDsEU-CTR / CTIS (EudraCT) 2023-504807-94-00, EU-CTR / CTIS (EudraCT) 2023-000442-41

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant, tamoxifen, or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Eli Lilly and Company

    Study Director

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

65 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States2 sites, 2 recruiting
  • Ellison Clinic at Saint John's

    Los Angeles

    Reva Basho
    Recruiting
  • Ucsf Medical Center at Mission Bay

    San Francisco

    Recruiting
Colorado, United States1 site, 1 recruiting
  • University of Colorado Cancer Center

    Aurora

    Anthony Elias
    Recruiting
Connecticut, United States1 site
  • Yale-New Haven Hospital

    New Haven

    Completed
Florida, United States2 sites, 1 recruiting
  • Florida Cancer Specialists Orlando/ddu

    Lake Mary

    Completed
  • Moffitt Cancer Center

    Tampa

    Aixa Soyano
    Recruiting
Georgia, United States1 site, 1 recruiting
  • Winship Cancer Institute, Emory University

    Atlanta

    Manali Bhave
    Recruiting
Iowa, United States1 site, 1 recruiting
  • University of Iowa

    Iowa City

    Mark Burkard
    Recruiting
Louisiana, United States1 site, 1 recruiting
  • Louisiana State University Health Sciences Center

    New Orleans

    Shou-Ching Tang
    Recruiting
Massachusetts, United States2 sites, 2 recruiting
  • Dana-Farber Cancer Institute

    Boston

    Antonio Giordano
    Recruiting
  • Massachusetts General Hospital

    Boston

    Dejan Juric
    Recruiting
Michigan, United States2 sites, 1 recruiting
  • Barbara Ann Karmanos Cancer Institute

    Detroit

    Terminated
  • Start Midwest

    Grand Rapids

    Manish Sharma
    Recruiting
Missouri, United States2 sites, 2 recruiting
  • Saint Luke's Cancer Institute

    Kansas City

    Timothy Pluard
    Recruiting
  • Washington University

    St Louis

    Cynthia Ma
    Recruiting
New York, United States1 site, 1 recruiting
  • Memorial Sloan Kettering Cancer Center

    New York

    Komal Jhaveri
    Recruiting
Ohio, United States2 sites, 2 recruiting
  • Uh Cleveland Medical Center

    Cleveland

    Alberto Montero
    Recruiting
  • Stefanie Spielman Comprehensive Breast Center

    Columbus

    Robert Wesolowski
    Recruiting
Oregon, United States1 site, 1 recruiting
  • Providence Cancer Institute Franz Clinic

    Portland

    David Page
    Recruiting
Tennessee, United States2 sites, 2 recruiting
  • the West Clinic, Pllc Dba West Cancer Center

    Germantown

    Gregory Vidal
    Recruiting
  • Sarah Cannon Research Institute

    Nashville

    SMO Sarah Cannon Research Inst.
    Recruiting
Texas, United States5 sites, 4 recruiting
  • Mary Crowley Cancer Research Center

    Dallas

    Completed
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas

    Joyce O'Shaughnessy
    Recruiting
  • University of Texas Southwestern

    Dallas

    Nisha Unni
    Recruiting
  • University of Texas Md Anderson Cancer Center

    Houston

    Jordi Rodon Ahnert
    Recruiting
  • Start San Antonio

    San Antonio

    Amita Patnaik
    Recruiting
Utah, United States1 site, 1 recruiting
  • Start Mountain Region

    West Valley City

    William McKean
    Recruiting
Virginia, United States1 site, 1 recruiting
  • Uso-Virginia Cancer Specialists, Pc

    Fairfax

    Alexander Spira
    Recruiting
Spain12 sites, 12 recruiting
  • Hospital Quiron Barcelona

    Barcelona

    Guzman Alonso Casal
    Recruiting
  • Hospital Universitari Vall D'Hebron

    Barcelona

    Cristina Saura Manich
    Recruiting
  • Instituto Oncologico Dr Rosell (ior)

    Barcelona

    Jose Manuel Perez Garcia
    Recruiting
  • South Texas Accelerated Research Therapeutics (start) Barcelona- Hm Nou Delfos

    Barcelona

    Tatiana Hernandez Guerrero
    Recruiting
  • Hospital San Pedro

    Logroño

    Maria Jose de Miguel Luken
    Recruiting
  • Hospital Clinico San Carlos

    Madrid

    Jorge Bartolome Arcilla
    Recruiting
  • Hospital Universitario Fundación Jiménez Díaz

    Madrid

    Bernard Doger de Speville Uribe
    Recruiting
  • Hospital Universitario Hm Sanchinarro

    Madrid

    Juan Jose Soto
    Recruiting
  • Md Anderson Cancer Center

    Madrid

    Maria Calvo Plaza
    Recruiting
  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón

    Valentina Boni
    Recruiting
  • Hospital Universitari Sant Joan de Reus

    Reus

    Kepa Amillano Parraga
    Recruiting
  • Hospital Universitario Virgen Macarena

    Seville

    Luis de la Cruz Merino
    Recruiting
Italy9 sites, 8 recruiting
  • Azienda Ospedaliera Nazionale Santi Antonio E Biagio E Cesare Arrigo

    Alessandria

    Giulia Gallizzi
    Recruiting
  • Spedali Civili Di Brescia

    Brescia

    Rebecca Pedersini
    Not, yet, recruiting
  • Istituto Europeo Di Oncologia

    Milan

    Giuseppe Curigliano
    Recruiting
  • Istituto Nazionale Per Lo Studio E la Cura Dei Tumori

    Milan

    Giulia Bianchi
    Recruiting
  • Fondazione Irccs San Gerardo Dei Tintori

    Monza

    Marina Cazzaniga
    Recruiting
  • Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara

    Pisa

    Carmelo Bengala
    Recruiting
  • Ospedale Santa Maria Delle Croci

    Ravenna

    Stefano Tamberi
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma

    Gennaro Daniele
    Recruiting
  • Centro Ricerche Cliniche Di Verona S.R.L.

    Verona

    Andrea Zivi
    Recruiting
France6 sites, 6 recruiting
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest

    Bordeaux

    Maxime Brunet
    Recruiting
  • Centre Leon Berard

    Lyon

    Isabelle Ray-Coquard
    Recruiting
  • Institut Paoli-Calmettes

    Marseille

    Cecile Vicier
    Recruiting
  • Centre Antoine-Lacassagne

    Nice

    Philippe Follana
    Recruiting
  • Institut Claudius Regaud

    Toulouse

    Eleonora De Maio
    Recruiting
  • Gustave Roussy

    Villejuif

    Barbara Pistilli
    Recruiting
Japan4 sites, 4 recruiting
  • National Hospital Organization Kyushu Cancer Center

    Fukuoka

    Eriko Tokunaga
    Recruiting
  • Kansai Medical University Hospital

    Hirakata

    Toshio Shimizu
    Recruiting
  • Kyoto University Hospital

    Kyoto

    TAKAKO NAKAJIMA
    Recruiting
  • the Cancer Institute Hospital of Jfcr

    Kōtō City

    Yukinori Ozaki
    Recruiting
Belgium2 sites, 2 recruiting
  • Institut Jules Bordet

    Anderlecht

    Philippe Aftimos
    Recruiting
  • Uz Leuven

    Leuven

    Patrick Neven
    Recruiting
Netherlands2 sites, 2 recruiting
  • Netherlands Cancer Institute

    Amsterdam

    Marloes G.J. van Dongen
    Recruiting
  • Erasmus Mc

    Rotterdam

    Agnes Jager
    Recruiting
Germany1 site
  • Universitätsklinikum Erlangen

    Erlangen

    Peter Fasching
    Not, yet, recruiting
Ireland1 site, 1 recruiting
  • Mater Misericordiae Hospital

    Dublin

    Austin Duffy
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 2 sites, 1 recruitingMI2New York: 1 site, 1 recruitingNY1Massachusetts: 2 sites, 2 recruitingMA2Rhode IslandRIOregon: 1 site, 1 recruitingOR1IdahoIDSouth DakotaSDIowa: 1 site, 1 recruitingIA1IllinoisILIndianaINOhio: 2 sites, 2 recruitingOH2PennsylvaniaPANew JerseyNJConnecticut: 1 siteCT1California: 2 sites, 2 recruitingCA2NevadaNVWyomingWYNebraskaNEMissouri: 2 sites, 2 recruitingMO2KentuckyKYWest VirginiaWVVirginia: 1 site, 1 recruitingVA1MarylandMDDelawareDEArizonaAZUtah: 1 site, 1 recruitingUT1Colorado: 1 site, 1 recruitingCO1KansasKSArkansasARTennessee: 2 sites, 2 recruitingTN2North CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisiana: 1 site, 1 recruitingLA1MississippiMSAlabamaALGeorgia: 1 site, 1 recruitingGA1HawaiiHITexas: 5 sites, 4 recruitingTX5Florida: 2 sites, 1 recruitingFL2District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Questions about NCT05768139

Each answer restates registry values shown on this page.

What is NCT05768139?

NCT05768139 is a phase 1/2 interventional trial sponsored by Eli Lilly and Company. It studies Abemaciclib, Anastrozole, Exemestane, Fulvestrant and 7 more drugs in Breast Cancer and Solid Tumors, Adult.

Is NCT05768139 recruiting?

As of 21 Nov 2026, it is recruiting participants. 59 of its 65 sites list their own status as recruiting.

Who leads NCT05768139?

The registry names Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (study director, Eli Lilly and Company) as the overall official.

Where does NCT05768139 run?

The registry lists 65 sites in 9 countries. Most sites are in these countries: United States (28), Spain (12) and Italy (9).

Which drugs does NCT05768139 study?

The registered drug and biological interventions are Abemaciclib, Anastrozole, Exemestane, Fulvestrant, Imlunestrant, Letrozole, Metformin, Palbociclib, Ribociclib, Tersolisib and Tamoxifen.

When is NCT05768139 expected to complete?

The registry lists a primary completion date of 31 Jul 2030 and a study completion date of 31 Jul 2030. The sponsor last updated the record on 7 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.